Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29445597 | 1.00 | CASP3 (0.54) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL14581384 | 1.00 | CASP3 (0.54) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL15223382 | 0.91 | CASP3 (0.53) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL31453048 | 0.91 | CASP3 (0.53) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL29445616 | 0.89 | CASP3 (0.51) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL13652772 | 0.89 | CASP3 (0.51) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL3269193 | 0.87 | CASP3 (0.56) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL13452269 | 0.87 | CASP3 (0.56) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL31068390 | 0.87 | CASP3 (0.56) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL5021152 | 0.87 | CASP3 (0.56) | CASP3KMT2AEPHX2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3099692-B9 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3521292-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | Pfizer Inc (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3099692-B1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-3342785-A1 | LINKERS FOR ANTIBODY-DRUG CONJUGATES | Daiichi Sankyo Company, Limited (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9605024-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160304560-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-20 | — | — | US | disclosed |
| US-9308236-B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-12 | — | — | US | disclosed |
| US-9303065-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| WO-2015110935-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20150158910-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-11 | — | — | US | disclosed |
| US-20140294898-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY | 2014-10-02 | — | — | US | disclosed |
| US-20140220047-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294898-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | CD274, PDCD1, PDCD1LG2 | CASP3 1644/4885KMT2A 2643/4885EPHX2 4863/4885 |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | CASP3 1437/4885KMT2A 3743/4885EPHX2 815/4885 |
| US-20140220047-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CASP3 2155/4885KMT2A 2858/4885EPHX2 3215/4885 |
| US-20180086793-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | CASP3 3617/4885KMT2A 3513/4885EPHX2 2816/4885 |
| US-20150158910-A1 | PAR4 AGONIST PEPTIDES | F2RL3, F2R, F2RL1 | CASP3 1091/4885KMT2A 2954/4885EPHX2 2577/4885 |
| US-20160304560-A1 | PAR4 AGONIST PEPTIDES | F2RL3, F2R, F2RL1 | CASP3 1091/4885KMT2A 2954/4885EPHX2 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.